Study of Immune Cells in Psoriasis Skin During Treatment with Anti-interleukin 23 Therapy in Adults with Moderate to Severe Plaque Psoriasis

What this Trial Is About

Psoriasis is a skin disease caused by immune system inflammation, leading to red and itchy plaques. It involves complex genetic and environmental factors. This research focuses on patients with moderate to severe psoriasis who are treated with anti-interleukin 23 IL-23 biologic drugs. The study aims to identify the cells producing key proteins that cause the disease to persist or relapse during treatment. Participants include those with moderate-severe psoriasis who have been on anti-IL-23 therapy for at least six months but still have resistant or relapsed skin lesions. Another group includes patients with moderate-severe psoriasis who have not yet received treatment. The study collects skin samples via a small punch biopsy from affected areas to analyze the immune cells involved. During the study, researchers will examine skin biopsies to identify immune cells producing cytokines linked to disease recurrence. They will also track immune markers related to sustained treatment response over about one year. Participants will provide informed consent, and their skin condition and immune markers will be monitored to better understand disease persistence during anti-IL-23 therapy.

Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)